IDEAS home Printed from https://ideas.repec.org/a/jpe/journl/1422.html

Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!

Author

Listed:
  • Raymond J. March

    (Texas Tech University)

Abstract

This paper finds that physicians and pharmaceutical companies working as entrepreneurial actors were able to better serve patients by finding effective alternative uses of three drugs. I examine off-label drug prescription within an entrepreneurial framework by examining the development processes of aspirin, Viagra, and minoxidil. In each case, the medical community reached research and treatment conclusions quicker than the FDA did. These examples provide counterevidence to the view that off-label prescription is reckless and requires additional governmental oversight due to a lack of sufficient testing. ______________________________________________________

Suggested Citation

  • Raymond J. March, 2017. "Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 32(3), pages 75-92.
  • Handle: RePEc:jpe:journl:1422
    as

    Download full text from publisher

    File URL: https://journal.apee.org/wp-content/uploads/journal/23869.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. McCarthy, Thomas R., 1985. "The competitive nature of the primary-care physician services market," Journal of Health Economics, Elsevier, vol. 4(2), pages 93-117, June.
    2. Bruce L. Benson, 2004. "Opportunities Forgone : The Unmeasurable Costs of Regulation," Journal of Private Enterprise, The Association of Private Enterprise Education, vol. 19(2), pages 1-25.
    3. Feldstein, Paul J., 1986. "The emergence of market competition in the U.S. health care system : Its causes, likely structure, and implications," Health Policy, Elsevier, vol. 6(1), pages 1-20.
    4. Schaumans, Catherine, 2015. "Prescribing behavior of General Practitioners: Competition matters," Health Policy, Elsevier, vol. 119(4), pages 456-463.
    5. Abe Dunn & Adam Hale Shapiro, 2018. "Physician Competition and the Provision of Care: Evidence from Heart Attacks," American Journal of Health Economics, MIT Press, vol. 4(2), pages 226-261, Spring.
    6. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. March, Raymond J. & Geloso, Vincent, 2020. "Gordon Tullock meets Phineas Gage: The political economy of lobotomies in the United States," Research Policy, Elsevier, vol. 49(1).
    2. Carson, Byron, 2025. "Reconsidering the normative foundations of public health: market vs. social justice," Journal of Economic Behavior & Organization, Elsevier, vol. 237(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Christopher S. Brunt & Joshua R. Hendrickson & John R. Bowblis, 2020. "Primary care competition and quality of care: Empirical evidence from Medicare," Health Economics, John Wiley & Sons, Ltd., vol. 29(9), pages 1048-1061, September.
    2. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
    3. Holger Patzelt & Dean A. Shepherd, 2009. "Strategic Entrepreneurship at Universities: Academic Entrepreneurs’ Assessment of Policy Programs," Entrepreneurship Theory and Practice, , vol. 33(1), pages 319-340, January.
    4. Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
    5. Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.
    6. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    7. Lorenz, Steffi, 2015. "Diversität und Verbundenheit der unternehmerischen Wissensbasis: Ein neuartiger Messansatz mit Indikatoren aus Innovationsprojekten," Discussion Papers on Strategy and Innovation 15-01, Philipps-University Marburg, Department of Technology and Innovation Management (TIM).
    8. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    9. Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
    10. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
    11. Carolyn M. Moehling & Gregory T. Niemesh & Melissa A. Thomasson & Jaret Treber, 2020. "Medical education reforms and the origins of the rural physician shortage," Cliometrica, Journal of Historical Economics and Econometric History, Association Française de Cliométrie (AFC), vol. 14(2), pages 181-225, May.
    12. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
    13. Janna L. Rose & Cassandra L. Quave & Gazi Islam, 2011. "The Four-Sided Triangle of Ethics in Bioprospecting: Pharmaceutical Business, International Politics, Socio-Environmental Responsibility and the Importance of Local Stakeholders," Business and Economics Working Papers 120, Unidade de Negocios e Economia, Insper.
    14. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    15. Abe C. Dunn & Lasanthi Fernando & Eli Liebman, 2024. "How Much Are Medical Innovations Worth? A Detailed Analysis Using Cost-Effectiveness Studies," BEA Papers 0132, Bureau of Economic Analysis.
    16. John J L Jacobs & Inés Beekers & Inge Verkouter & Levi B Richards & Alexandra Vegelien & Lizan D Bloemsma & Vera A M C Bongaerts & Jacqueline Cloos & Frederik Erkens & Patrycja Gradowska & Simon Hort , 2025. "A data management system for precision medicine," PLOS Digital Health, Public Library of Science, vol. 4(1), pages 1-21, January.
    17. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    18. Josh Feng & Luca Maini, 2024. "Demand Inertia and the Hidden Impact of Pharmacy Benefit Managers," Management Science, INFORMS, vol. 70(12), pages 8940-8961, December.
    19. Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
    20. Waters, James, 2014. "Introduction of innovations during the 2007-8 financial crisis: US companies compared with universities," MPRA Paper 59016, University Library of Munich, Germany.

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:jpe:journl:1422. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/apeeeea.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.